Works matching DE "EMPAGLIFLOZIN"

Results: 1064
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18

    The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms.

    Published in:
    Journal of Clinical Medicine, 2023, v. 12, n. 4, p. 1356, doi. 10.3390/jcm12041356
    By:
    • Semo, Dilvin;
    • Obergassel, Julius;
    • Dorenkamp, Marc;
    • Hemling, Pia;
    • Strutz, Jasmin;
    • Hiden, Ursula;
    • Müller, Nicolle;
    • Müller, Ulrich Alfons;
    • Zulfikar, Sajan Ahmad;
    • Godfrey, Rinesh;
    • Waltenberger, Johannes
    Publication type:
    Article
    19
    20
    21
    22

    Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure.

    Published in:
    Journal of Clinical Medicine, 2021, v. 10, n. 16, p. 3540, doi. 10.3390/jcm10163540
    By:
    • Pérez-Belmonte, Luis M.;
    • Ricci, Michele;
    • Sanz-Cánovas, Jaime;
    • Millán-Gómez, Mercedes;
    • Osuna-Sánchez, Julio;
    • Ruiz-Moreno, M. Isabel;
    • Bernal-López, M. Rosa;
    • López-Carmona, María D.;
    • Jiménez-Navarro, Manuel;
    • Gómez-Doblas, Juan J.;
    • Lara, José P.;
    • Gómez-Huelgas, Ricardo
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40

    Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double‐blind trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2025, v. 27, n. 7, p. 3943, doi. 10.1111/dom.16431
    By:
    • van Baar, Michaël J. B.;
    • Muskiet, Marcel H. A.;
    • Scholtes, Rosalie A.;
    • Touw, Daan J.;
    • Nieuwdorp, Max;
    • Kramer, Mark H. H.;
    • Joles, Jaap A.;
    • Cherney, David Z. I.;
    • Bjornstad, Petter;
    • Krebber, Merle M.;
    • van Raalte, Daniël H.
    Publication type:
    Article
    41
    42
    43
    44
    45
    46

    Comparative analysis of hospitalization risk for incident heart failure in non‐Hispanic Black versus non‐Hispanic White individuals with type 2 diabetes on empagliflozin (Empa‐AA): Insights from real‐world data.

    Published in:
    Diabetes, Obesity & Metabolism, 2024, v. 26, n. 5, p. 1830, doi. 10.1111/dom.15499
    By:
    • Mishriky, Basem M.;
    • Cummings, Doyle M.;
    • Fu, Yuanyuan;
    • Halladay, Jacqueline R.;
    • Jones, Schuyler;
    • Boan, Andrea D.;
    • Jones, Sara;
    • Patil, Shivajirao P.;
    • Powell, James R.;
    • Adams, Alyssa;
    • Irish, William
    Publication type:
    Article
    47

    Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts.

    Published in:
    Diabetes, Obesity & Metabolism, 2024, v. 26, n. 4, p. 1291, doi. 10.1111/dom.15429
    By:
    • Rebordosa, Cristina;
    • Thomsen, Reimar W.;
    • Tave, Arlene K.;
    • Madsen, Morten;
    • Beachler, Daniel C.;
    • Martinez, David;
    • Garcia‐Esteban, Raquel;
    • Plana, Estel;
    • Tormos, Anita;
    • Farsani, Soulmaz Fazeli;
    • Perez‐Gutthann, Susana;
    • Pladevall‐Vila, Manel
    Publication type:
    Article
    48
    49
    50